Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple combination therapy for recurrent/metastatic head and neck squamous cell carcinoma
ISRCTN17533723Phase 2Completed
- Sponsor
- Taipei Veterans General Hospital
- Start
- Jun 2010
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan, cisplatin and tegafur + uracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Taipei Veterans General Hospital. Primary endpoints: Recommended dose of irinotecan and Overall objective response rate. Started Jun 2010; status: completed.
02
Drugs
irinotecancisplatintegafur + uracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN17533723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17533723.